IN THE CLAIMS:

Claim 1 (**currently amended**): A compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof:



(I)

wherein

Y is selected from a bond, -S-, -O-, $-NR^5-$, $-CF_2-CH_2-$, $-CF_2CF_2-$, $-CONR^5-$, phenyl or ~~heteroaryl.~~ heteroaryl; ~~wherein~~

R^1 is a group selected from C_{3-7}carbocyclyl, C_{1-8}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl,~~;~~ which ~~wherein the~~ group is optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, nitrile, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, phenyl or heteroaryl~~;~~ and wherein phenyl and heteroaryl are optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6}alkyl and trifluoromethyl; ~~wherein~~

R^2 is C_{3-7}carbocyclyl, optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, $-OR^4$, $-NR^5R^6$ $-CONR^5R^6$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$;

or R^2 is a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S, $-NR^8$ and ~~whereby the~~ which ring is optionally substituted by C_{1-3}alkyl or fluoro;

or R^2 is a phenyl or heteroaryl, each of which is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-NR^8COR^9$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6}alkyl and trifluoromethyl;

or R^2 is a group selected from C_{1-8}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl, which ~~wherein the~~ group is substituted by 1, 2 or 3 substituents independently selected from hydroxy, amino, C_{1-}

$_{6}$alkoxy, C_{1-6}alkylamino, di(C_{1-6}alkyl)amino, *N*-(C_{1-6}alkyl)-*N* –(phenyl)amino, *N*-C_{1-6}alkylcarbamoyl, *N,N*-di(C_{1-6}alkyl)carbamoyl, *N*-(C_{1-6}alkyl)-*N* –(phenyl)carbamoyl, carboxy, phenoxycarbonyl, $-NR^8COR^9$, $-SO_2R^{10}$, $-SO_2NR^5R^6$ and $-NR^8SO_2R^9$; ~~wherein~~

R^3 is hydrogen or independently R^2;

R^4 is hydrogen or a group selected from C_{1-6}alkyl and phenyl, which ~~wherein the~~ group is optionally substituted by 1 or 2 substituents independently selected from halo, phenyl, $-OR^{11}$ and $-NR^{12}R^{13}$;

R^5 and R^6 are independently hydrogen or a group selected from C_{1-6}alkyl and phenyl, which ~~wherein the~~ group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{14}$,$-NR^{15}R^{16}$, $-COOR^{14}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$ and $NR^{15}SO_2R^{16}$;

or R^5 and R^6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally containing a further heteroatom selected from oxygen and nitrogen atoms, which ring is optionally substituted by 1, 2 or 3 substituents independently selected from phenyl, $-OR^{14}$, $-COOR^{14}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$, $NR^{15}SO_2R^{16}$ or C_{1-6}alkyl (optionally substituted by 1 or 2 substituents independently selected from halo, $-NR^{15}R^{16}$ and $-OR^{17}$ groups);

R^{10} is hydrogen or a group selected from C_{1-6}alkyl or phenyl, which ~~wherein the~~ group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$; ~~and~~ each of R^7, R^8, R^9, R^{11}, R^{12}, R^{13}, R^{14} R^{15}, R^{16}, R^{17} is independently hydrogen, C_{1-6}alkyl or phenyl;

R^x is trifluoromethyl, $-NR^5R^6$, phenyl, napthyl, monocyclic or bicyclic heteroaryl, which ~~wherein a~~ heteroring may be partially or fully saturated and one or more ring carbon atoms may form a carbonyl group, and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6}alkyl or trifluoromethyl;;

or R^x is a group selected from C_{3-7}carbocyclyl, C_{1-8}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl, which ~~whereby the~~ group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$,$-COOR^7$, $-NR^8COR^9$, $-SR^{10}$,

$-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, phenyl or heteroaryl~~,~~; and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6}alkyl or trifluoromethyl. ~~trifluoromethyl;~~

Claim 2 (**original**): A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 wherein R^2 is C_{1-8}alkyl optionally substituted by 1 or 2 hydroxy substituents.

Claim 3 (**original**): A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 wherein R^1 is benzyl or $-CH_2CH_2OPh$, or CH_2CH_2Ph wherein in each case the phenyl ring is optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, chloro, bromo, methoxy, methyl and trifluoromethyl.

Claim 4 (**currently amended**): A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 wherein R^3 is hydrogen.

Claim 5 (**currently amended**): A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 wherein Y is selected from a bond, -S-, and $-CF_2-CH_2-$ and $-CH_2-CH_2-$.

Claim 6 (**currently amended**): A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 wherein R^x is methyl,1-methylimidazolyl, 1,2-dimethylimidazolyl, *N,N*-dimethylamino, azetidinyl, pyrolidinyl, morpholinyl, piperidinyl and trifluoroethyl. ~~trifluoromethyl~~

Claim 7 (**currently amended**): A compound selected from the group consisting of:

N-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-methanesulfonamide; ~~and~~

N-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-1-azetidinesulfonamide;~~,~~

N-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-methanesulfonamide;

N-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-1-azetidinesulfonamide;

4-morpholinesulfonamide, *N*-[4-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-;

methanesulfonamide, *N*-[4-[[2-(2,3-difluorophenoxy)ethyl]thio]-6-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-; and

methanesulfonamide, 1,1,1-trifluoro-*N*-[4-[[(1*R*)-2-hydroxy-1-methylethyl]amino]-6-(2-phenylethyl)-1,3,5-triazin-2-yl]-;

or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof.

Claims 8-13 (**cancelled**).

Claim 14 (**currently amended**): A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1, ~~any one of claims 1 to 7;~~ and a pharmaceutically-acceptable diluent or carrier.

Claim 15 (**currently amended**): A process for the preparation of a compound according to claim 1 or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, which comprises the steps of:

treating a compound of formula (2):



(2)

wherein Y, R^1, R^2 and R^3 are as defined in claim 1, ~~formula (1)~~ with a sulfonamide of formula $R^xSO_2NH_2$ where R^x is as defined in claim 1 ~~formula (1)~~;

and optionally thereafter, one or more of steps (i), (ii), (iii), (iv), or (v) in any order:

i) removing any protecting groups;

ii) converting the compound of formula (1) into a further compound of formula (1);

iii) forming a salt;

iv) forming a prodrug;

v) forming an *in vivo* hydrolysable ester.

Claim 16 (**currently amended**): A combination therapy which comprises administering a compound of formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmcaceutical composition or formulation comprising a compound of formula (1), concurrently or sequentially with other therapy and/or another pharmaceutical agent.

Claim 17 (**currently amended**): ~~A~~ The combination therapy as claimed in claim 16 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

Claim 18 (**currently amended**): ~~A~~ The combination therapy as claimed in claim 16 for the treatment of cancer.

Claim 19 (**currently amended**): A pharmaceutical composition which comprises a compound of formula (1) according to claim 1 or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, in conjunction with another pharmaceutical agent.

Claims 20-21 (**cancelled**).

Claim 22 (**new**): A method of treating a disease or medical condition selected from asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis in a warm-blooded animal in need thereof, the method comprising administering to said animal an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof.

Claim 23 (**new**): A method of treating cancer in a warm-blooded animal in need thereof, the method comprising administering to said animal an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof.

Claim 24 (**new**): A method of treating a disease or medical condition mediated by the modulation of chemokine receptor activity, the method comprising administering to said animal an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof.